verve therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease. the company brings together human genetics analysis and gene editing – two of the biggest breakthroughs in 21st century biomedicine – to develop transformative therapies for coronary heart disease. verve is developing medicines, administered once in life, to safely edit the genome of adults to permanently lower ldl cholesterol and triglyceride levels and thereby treat coronary heart disease. founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, verve is backed by a top-tier syndicate of investors, including gv (formerly google ventures), arch venture partners, f-prime capital, biomatics capital, wellington management, casdin capital, and partners innovation fund. the company was recognized as a "2020 best places to work" by the boston business journal. verve is headquartered in cambridge, massachusetts.
![Verve Therapeutics logo](/files/LOGO/1840574-VERV.png)
Company profile
Ticker
VERV
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
Corporate docs
IRS number
824800132
VERV stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
28 Jun 24
8-K/A
Submission of Matters to a Vote of Security Holders
28 Jun 24
8-K
Submission of Matters to a Vote of Security Holders
7 Jun 24
8-K
Departure of Directors or Certain Officers
31 May 24
10-Q
2024 Q1
Quarterly report
8 May 24
8-K
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
8 May 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
8-K
Other Events
2 Apr 24
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 148.97 mm | 148.97 mm | 148.97 mm | 148.97 mm | 148.97 mm | 148.97 mm |
Cash burn (monthly) | 20.66 mm | (no burn) | 18.95 mm | 18.48 mm | 14.36 mm | 11.96 mm |
Cash used (since last report) | 79.89 mm | n/a | 73.27 mm | 71.45 mm | 55.53 mm | 46.25 mm |
Cash remaining | 69.08 mm | n/a | 75.70 mm | 77.53 mm | 93.44 mm | 102.72 mm |
Runway (months of cash) | 3.3 | n/a | 4.0 | 4.2 | 6.5 | 8.6 |
Institutional ownership, Q1 2024
13F holders | Current |
---|---|
Total holders | 159 |
Opened positions | 68 |
Closed positions | 22 |
Increased positions | 50 |
Reduced positions | 24 |
13F shares | Current |
---|---|
Total value | 1.01 tn |
Total shares | 97.65 mm |
Total puts | 172.60 k |
Total calls | 122.50 k |
Total put/call ratio | 1.4 |
Largest owners | Shares | Value |
---|---|---|
GOOG Alphabet Inc - Ordinary Shares | 12.35 mm | $164.00 bn |
GV 2017 | 12.35 mm | $145.60 mm |
Vanguard | 6.33 mm | $84.08 bn |
ARK Investment Management | 6.04 mm | $80.22 bn |
BLK Blackrock | 5.37 mm | $71.36 bn |
STT State Street | 5.10 mm | $67.69 bn |
T. Rowe Price Investment Management | 4.58 mm | $60.78 mm |
FHI Federated Hermes Inc - Ordinary Shares | 3.56 mm | $47.23 bn |
FMR | 3.38 mm | $44.85 bn |
Casdin Capital | 3.06 mm | $40.62 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Jun 24 | Sekar Kathiresan | Common Stock | Option exercise | Acquire M | No | No | 2.87 | 30,000 | 86.10 k | 351,128 |
28 Jun 24 | Sekar Kathiresan | Stock Option Common Stock | Option exercise | Dispose M | No | No | 2.87 | 30,000 | 86.10 k | 215,308 |
26 Jun 24 | Krishna Yeshwant | Stock Option Common Stock | Grant | Acquire A | No | No | 5.02 | 136,139 | 683.42 k | 136,139 |
News
Cathie Wood's Ark Invest Dumps Another $3.25M Worth Of Tesla Shares Amid Searing Q2 Deliveries Rally
3 Jul 24
Cathie Wood-Led Ark Invest Sells $1.5M Worth Of Robinhood Shares Amid Muted Bitcoin Market — Also Dumps Zoom Stock Worth $3.3M
12 Jun 24
Cathie Wood-Lead Ark Invest Dumps $7.6M Worth Of Robinhood Shares Amid GameStop Buzz, Bitcoin Choppiness
10 Jun 24
Cathie Wood-Led Ark Invest Buys $9.9M Worth Of Amazon Shares, Also Picks Up Reddit Stock
6 Jun 24
Cathie Wood's Ark Innovation ETF Sees Sharp Decline Among Top Holdings — Here Are 10-Largest Losers Within ARKF
28 May 24
Press releases
VERV The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc.
9 Jul 24
VERV Investors Have the Opportunity to Join Investigation of Verve Therapeutics, Inc. with the Schall Law Firm
20 Jun 24
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
31 May 24
Verve Therapeutics Announces Leadership Update
31 May 24
Verve Therapeutics to Participate in Upcoming Investor Conferences
30 May 24